Furthermore, patients with TSC2-polycystic kidney disease 1 deletion syndrome and hypertension treated with inhibition of the RAS pathway via angiotensin receptor blockade had decreased renal AML development compared to those who did not receive this therapy (22). Here, TSC2 is linked to hypertensive disorder.